GAIN THERAPEUTICS, INC Operating Leases, Future Minimum Payments, Due in Rolling Year Two
GAIN THERAPEUTICS, INC (GANX) had Operating Leases, Future Minimum Payments, Due in Rolling Year Two of $170.40 thousand as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo · last filed 2023-11-14
- 2023-09-30: Operating Leases, Future Minimum Payments, Due in Rolling Year Two $170.40K.
- 2023-06-30: Operating Leases, Future Minimum Payments, Due in Rolling Year Two $192.03K.
- 2023-03-31: Operating Leases, Future Minimum Payments, Due in Rolling Year Two $207.79K.
- 2022-09-30: Operating Leases, Future Minimum Payments, Due in Rolling Year Two $229.56K.
| Period end | Operating Leases, Future Minimum Payments, Due in Rolling Year Two |
|---|---|
| 2023-09-30 | $170.40K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $192.03K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $207.79K 10-Q · filed 2023-05-12 |
| 2022-09-30 | $229.56K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $234.35K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |